Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Inclusion Criteria: * Patients \>18 years affected by advanced or metastatic HCC previously treated with no more than one systemic therapeutic regimen * Histologically confirmed HCC not amenable to curative surgery * Child-Pugh scale class A * ECOG Performance status 0 - 1 * Patients in progression disease at study entry CT documented * Adequate baseline bone marrow, hepatic and renal function, defined as follows: * Neutrophils \> 1.5 x 10\^9/L and platelets \> 100 x 10\^9/L * Bilirubin \< 2 x ULN * Transaminases \< 3 x ULN * Absence of any conditions in which hypervolaemia and its consequences (e.g. increased stroke volume, elevated blood pressure) or haemodilution could represent a risk for the patient (reference appendix "Technical data sheet human albumin") * Normal cardiac function and absence of uncontrolled hypertension * Patients must give written informed consent Exclusion criteria: * Decompensated cirrhosis (Child-Pugh score \>7) * Concurrent anticancer therapy * Patients may not receive any other investigational agents while on study * Clinical signs of CNS involvement * Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol * Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol * Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration